London, United Kingdom

John Hugh Lyon Playfair

This inventor holds 1 USPTO granted patent. Top assignee: Rademacher Group Limited. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Hugh Lyon Playfair. Retrieved from https://idiyas.com/inventor/john-hugh-lyon-playfair

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Hugh Lyon Playfair: Innovator in Diabetes Treatment

Introduction

John Hugh Lyon Playfair is a notable inventor based in London, GB. He has made significant contributions to the field of medical science, particularly in the treatment of diabetes. His innovative approach has garnered attention and recognition within the scientific community.

Latest Patents

Playfair holds a patent for a groundbreaking method in the treatment of non-insulin dependent diabetes mellitus (NIDDM). The patent outlines the use of a killed malaria parasite or an extract thereof as a therapeutic option for managing this condition. This innovative treatment approach has the potential to change the way diabetes is managed.

Career Highlights

Playfair is associated with Rademacher Group Limited, where he applies his expertise in medical research and innovation. His work has been instrumental in advancing treatment options for diabetes, showcasing his commitment to improving patient outcomes.

Collaborations

Throughout his career, Playfair has collaborated with esteemed colleagues such as Khaled Elased and Joseph Brian De Souza. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in medical research.

Conclusion

John Hugh Lyon Playfair's contributions to diabetes treatment exemplify the impact of innovative thinking in medicine. His patent and collaborative efforts highlight the importance of research in developing new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…